Osteoporosis Medicines and Dental Implants: The Facts

Osteoporosis medicines do not automatically rule out dental implants, but some require particular assessment before procedures involving jawbone. Certain antiresorptive medicines, which reduce bone breakdown, and antiangiogenic medicines, which affect blood-vessel growth, are associated with medication-related osteonecrosis of the jaw, or MRONJ. Risk varies with the drug, dose, route, duration, reason for treatment, health and oral condition; osteoporosis care and high-dose cancer treatment are not equivalent.

Do not stop bone medication without the prescriber

Do not interrupt bone treatment without advice from the prescribing team. Some interruptions can create serious medical risks. Any proposed timing change needs coordinated assessment rather than a self-directed drug holiday. SDCEP guidance distinguishes risk groups and emphasises dental health, infection prevention and careful planning of procedures affecting bone.

What a considered implant assessment asks

The clinician should record the medicine and its purpose, previous doses and treatment dates, dental infections, gum disease, smoking and overall health. Compare an implant with bridges, dentures or stabilisation of existing teeth, including the risks of doing nothing. A specialist opinion may be appropriate in higher-risk cases. Procedures should not be marketed as risk-free simply because a modern implant system is used.

Bring the information that changes decisions

Bring medication packaging or a complete prescription list and relevant letters from your GP, osteoporosis service or oncologist. Confirm who will liaise with the prescriber and what aftercare and warning signs apply. Non-healing sores, exposed bone, persistent pain, discharge or swelling should be reported promptly. The aim is to support necessary medical treatment while planning appropriate oral care.

Bone medicines change the conversation, not necessarily the answer

People taking treatment for osteoporosis sometimes assume implants are impossible. That is too broad. Risk depends on the medication, route, dose, duration and reason for treatment, as well as dental disease and other individual factors. An oral antiresorptive used for osteoporosis is not automatically equivalent to the higher-dose intravenous regimens sometimes used in cancer care. Medication-related osteonecrosis of the jaw is a relevant consideration for some invasive procedures, but it should be discussed with actual risk factors rather than used to frighten patients or guarantee safety.

Bring a precise medication history

Tell the dentist the drug name, dose, how it is given, when it started and whether you previously received related medicines. Other relevant issues include steroid treatment, smoking, gum disease, diabetes and any history of jaw problems. The dental team may need to contact the prescribing clinician for clarification. Do not stop or defer osteoporosis treatment on your own initiative: changes can create important medical consequences, and any adjustment must be considered with the treating medical team. A consultation without complete medication information cannot provide a reliable implant recommendation.

Alternatives have different trade-offs

For a missing tooth, suitable choices may include an implant, a conventional or adhesive bridge, a denture or monitoring. An implant avoids using neighbouring teeth for support but needs an assessment of surgical risk. A bridge may avoid implant placement yet require alteration of intact teeth. The location and condition of the mouth, alongside each option's preparation and maintenance, guide a proportionate choice.

Treatment planning should be explicit

Where an implant pathway is reasonable, the dentist must examine available bone, periodontal stability and how the final restoration would be cleaned. Written consent should cover the specific medication-related considerations, possible healing difficulties and what support is available if complications occur. If a more cautious approach is chosen, ask why and whether the decision might change with improved oral health or further medical information. For a first-time implant consultation in North London, the most useful preparation is a complete medicines list and an honest discussion of the tooth-replacement goal.

Questions worth sharing with the prescriber

The dentist may want to know the indication for treatment, the risk of fracture if a drug were interrupted and whether medical advice is needed before an invasive procedure. For a person taking denosumab, timing and unplanned interruption can have particular medical implications; this is a matter for coordinated professional judgement. A safe consultation should explain what information is missing and who will obtain it, rather than casually recommending a medication holiday. The SDCEP guidance separates patients into different risk categories and explicitly warns against discouraging necessary antiresorptive therapy through exaggerated risk claims.